证券代码：603387 证券简称：基蛋生物 公告编号：2025-038 基蛋生物科技股份有限公司 关于聘任证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）原证券事务代表谢玉鑫先 生因工作变动，向董事会递交辞呈，提请辞去公司证券事务代表职务。谢玉鑫先 生在担任公司证券事务代表期间恪尽职守、勤勉尽责，董事会对其在任期间为公 司作出的积极贡献表示衷心的感谢！ 公司于2025年8月29日召开第四届董事会第七次会议，审议通过了《关于聘 任证券事务代表的议案》，公司董事会同意聘请王娇女士为公司证券事务代表， 协助董事会秘书履行职责。任期自本次董事会审议通过之日起至第四届董事会届 满为止。王娇女士已取得上海证券交易所董事会秘书任职培训证明，具备履行职 责所必需的专业能力，其任职资格符合《上海证券交易所股票上市规则》等相关 规定。 公司证券事务代表的联系方式如下： 电话：025-68568577 电子邮箱：IR@getein.cn 联系地址：南京市六合区沿江工业开发区博富路9号 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company,基蛋生物, within the medical device industry [1][2] - As of August 22, the company's stock closed at 8.83 yuan, down 2.11%, with a rolling PE ratio of 22.18 times and a total market capitalization of 4.478 billion yuan [1] - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing the company at the 47th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, the number of shareholders for the company is 26,747, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1]

Group 1 - The core viewpoint of the articles highlights the current financial performance and market position of 基蛋生物, indicating a significant decline in revenue and profit compared to the previous year [1][2] - As of August 19, 基蛋生物's closing stock price was 8.9 yuan, with a PE ratio of 22.35, marking a new low in 165 days, and a total market capitalization of 4.514 billion yuan [1] - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning 基蛋生物 at 46th place within the industry [1][2] Group 2 - For the first quarter of 2025, 基蛋生物 reported revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24% year-on-year, with a gross margin of 77.15% [1] - The company is primarily engaged in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field in China [1] - As of March 31, 2025, 基蛋生物 had 26,747 shareholders, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Summary of Key Points Core Viewpoint - Nanjing Aiji Business Information Consulting Co., Ltd. has completed its share reduction plan for G-Bio Technology Co., Ltd., reducing its holdings by 666,600 shares, which is 0.1314% of the total share capital [1][5]. Shareholder Holding Situation - Nanjing Aiji holds 16,881,219 shares of G-Bio, representing 3.33% of the total share capital, acquired through pre-IPO holdings and capital reserve conversion [1]. Implementation of Reduction Plan - The reduction plan was fully executed, with a slight difference of 25 shares from the planned reduction due to unexecuted fractional shares [5]. - Key executives, including the vice general managers and financial director, reduced their holdings through Nanjing Aiji, with specific reductions detailed for each [5]. Major Shareholder and Executive Actions - The controlling shareholder, Su Enben, did not reduce his indirect holdings during this share reduction process [2][5]. - The actual reduction matched the previously disclosed plan, confirming that the plan was executed as intended [6].

Shareholder Reduction - Boliview's chairman Zhang Zhiping plans to reduce holdings by no more than 2.3756 million shares [1] - Weitang Industrial's specific shareholder Gaoxin Venture plans to reduce holdings by no more than 701,400 shares [1] - Jizhi Technology's Jiyang Investment plans to reduce holdings by no more than 1.05% of shares [1] - Aosaikang's shareholder Zhongyi Weiye plans to reduce holdings by no more than 2% of shares [1] - Shutaishen's shareholder Xiangtang Group plans to reduce holdings by no more than 2% of shares [1] - Qinsong's shareholder Ruizhong Life plans to reduce holdings by no more than 1% of shares [1] - Changchun Yidong's shareholder FAW Equity Company plans to reduce holdings by no more than 2.97% of shares [1] - Sirui Pu's director and deputy general manager Feng Ying plans to reduce holdings by no more than 540,000 shares [1] - Bixing Wulian's Biyuan has cumulatively reduced 1% of the company's shares [1] - Jidan Biological's Nanjing Aiji has cumulatively reduced 666,600 shares [1] Financial Performance - Leike Defense reported a net loss of 41.6721 million yuan in the first half of the year [1] - Zhenhua New Materials reported a net loss of 217 million yuan in the first half of the year [1]

Core Viewpoint - The company,基蛋生物, has reported a complete reliance on in vitro diagnostics for its revenue in 2024, indicating a focused business model in this sector [1]. Group 1: Shareholder Actions - 南京爱基 has completed its share reduction plan, having reduced approximately 670,000 shares, which represents 0.1314% of the total share capital of about 507 million shares [3]. - The actual number of shares reduced was very close to the planned amount, with a difference of only 25 shares due to unexecuted fractional shares [3]. - Key executives, including the company's vice president and financial director, have also reduced their holdings through 南京爱基, with the total reductions by these individuals being within 25% of their indirect holdings [3].

证券代码：603387 证券简称：基蛋生物 公告编号：2025-028 基蛋生物科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 南京爱基商务信息咨询有限公司（以下简称"南京爱基"）为基蛋生物科技 股份有限公司（以下简称"公司"或"基蛋生物"）的员工持股平台。截止本公 告披露日，南京爱基持有基蛋生物股份 16,881,219 股,占公司总股本的 3.33%。 以上股份来源为首次公开发行前持有的股份及上市后资本公积转增股本方式取 得的股份。 减持计划的实施结果情况：截至本公告披露日，南京爱基通过集中竞价 交易方式累计减持 666,600 股，占公司总股本 507,153,517 股的 0.1314%。公司 于 2025 年 8 月 15 日收到股东爱基发来的《关于减持股份计划实施结果的告知函》， 南京爱基本次减持计划实施完毕。 本次南京爱基减持的股份中不包含公司实控人苏恩本先生在南京爱基持 有的份额，在本次减持中，苏恩本先生未以任何方式减持其在南 ...

Group 1 - The core point of the article is that the company, G-Bio, has announced the completion of a share reduction plan by its shareholder, Nanjing Aiji, which involved a total reduction of 666,600 shares, accounting for 0.1314% of the company's total share capital [1] Group 2 - Nanjing Aiji executed the share reduction through centralized bidding transactions [1] - The completion of the share reduction plan was communicated to the company on August 15, 2025 [1]

Group 1 - The core point of the article is that the company, G-Bio, has announced the completion of a share reduction plan by its shareholder, Nanjing Aiji, which involved a total reduction of 666,600 shares, accounting for 0.1314% of the company's total share capital [1] Group 2 - Nanjing Aiji executed the share reduction through centralized bidding transactions [1] - The completion of the share reduction plan was communicated to the company on August 15, 2025 [1]

Core Viewpoint - The company,基蛋生物, is currently facing a decline in stock price and performance metrics, with a significant gap between its price-to-earnings ratio and the industry average, indicating potential undervaluation in the context of its sector [1][2]. Company Summary - 基蛋生物's closing stock price is 8.67 yuan, down 1.25%, with a rolling PE ratio of 21.77 times and a total market capitalization of 4.397 billion yuan [1]. - The company specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, particularly in the POCT (Point of Care Testing) field, and is recognized as a key high-tech enterprise under the National Torch Program [1]. - The latest quarterly report for Q1 2025 shows a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning 基蛋生物 at the 46th rank within the industry [1][2]. - The industry shows a wide range of PE ratios, with the highest being 20.62 times for 安图生物 and the lowest at 11.18 times for 九安医疗, indicating varying levels of market valuation across different companies [2].